{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:28:08Z","timestamp":1786980488716,"version":"build-2736575974"},"reference-count":110,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T00:00:00Z","timestamp":1682380800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T00:00:00Z","timestamp":1682380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s10067-023-06605-9","type":"journal-article","created":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T05:02:43Z","timestamp":1682398963000},"page":"2251-2265","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Difficult to treat psoriatic arthritis \u2014 how should we manage?"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7374-5837","authenticated-orcid":false,"given":"Anand","family":"Kumthekar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maedeh","family":"Ashrafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Deodhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,25]]},"reference":[{"issue":"5","key":"6605_CR1","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1136\/annrheumdis-2012-201706","volume":"72","author":"M Haroon","year":"2013","unstructured":"Haroon M, Kirby B, FitzGerald O (2013) High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires. Ann Rheumatic Dis 72(5):736\u201340","journal-title":"Ann Rheumatic Dis"},{"issue":"1","key":"6605_CR2","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jaad.2018.06.027","volume":"80","author":"F Alinaghi","year":"2019","unstructured":"Alinaghi F, Calov M, Kristensen LE, Gladman DD, Coates LC, Jullien D et al (2019) Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 80(1):251\u201365 e19","journal-title":"J Am Acad Dermatol."},{"issue":"9","key":"6605_CR3","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1136\/ard.2008.094946","volume":"68","author":"CT Ritchlin","year":"2009","unstructured":"Ritchlin CT, Kavanaugh A, Gladman DD, Mease PJ, Helliwell P, Boehncke W-H et al (2009) Treatment recommendations for psoriatic arthritis. Ann Rheumatic Dis 68(9):1387\u201394","journal-title":"Ann Rheumatic Dis"},{"issue":"10","key":"6605_CR4","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1056\/NEJMra1505557","volume":"376","author":"CT Ritchlin","year":"2017","unstructured":"Ritchlin CT, Colbert RA, Gladman DD (2017) Psoriatic arthritis. New Eng J Med 376(10):957\u201370","journal-title":"New Eng J Med"},{"issue":"6","key":"6605_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11926-021-00999-8","volume":"23","author":"DD Gladman","year":"2021","unstructured":"Gladman DD (2021) Axial psoriatic arthritis. Curr Rheumatol Rep 23(6):1\u20137","journal-title":"Curr Rheumatol Rep"},{"issue":"2","key":"6605_CR6","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s00296-020-04775-2","volume":"41","author":"S Gupta","year":"2021","unstructured":"Gupta S, Syrimi Z, Hughes DM, Zhao SS (2021) Comorbidities in psoriatic arthritis: a systematic review and meta-analysis. Rheumatol Int 41(2):275\u201384","journal-title":"Rheumatol Int"},{"issue":"6","key":"6605_CR7","first-page":"S83","volume":"24","author":"A Kavanaugh","year":"2006","unstructured":"Kavanaugh A, Fransen J (2006) Defining remission in psoriatic arthritis. Clin Exp Rheumatol 24(6):S83","journal-title":"Clin Exp Rheumatol"},{"issue":"8","key":"6605_CR8","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1093\/rheumatology\/kex344","volume":"57","author":"LC Coates","year":"2018","unstructured":"Coates LC, Conaghan PG, D\u2019Agostino MA, De Wit M, FitzGerald O, Kvien TK et al (2018) Remission in psoriatic arthritis\u2014where are we now? Rheumatology. 57(8):1321\u201331","journal-title":"Rheumatology."},{"issue":"01","key":"6605_CR9","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1136\/ard.2008.102053","volume":"69","author":"LC Coates","year":"2010","unstructured":"Coates LC, Fransen J, Helliwell PS (2010) Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis 69(01):48\u201353","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"6605_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2017-211734","volume":"77","author":"JS Smolen","year":"2018","unstructured":"Smolen JS, Schols M, Braun J, Dougados M, FitzGerald O, Gladman DD et al (2018) Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis. 77(1):3\u201317","journal-title":"Ann Rheum Dis."},{"issue":"4","key":"6605_CR11","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1136\/annrheumdis-2016-210283","volume":"76","author":"B Michelsen","year":"2017","unstructured":"Michelsen B, Kristianslund EK, Hammer HB, Fagerli KM, Lie E, Wierod A et al (2017) Discordance between tender and swollen joint count as well as patient\u2019s and evaluator\u2019s global assessment may reduce likelihood of remission in patients with rheumatoid arthritis and psoriatic arthritis: data from the prospective multicentre NOR-DMARD study. Ann Rheum Dis. 76(4):708\u201311","journal-title":"Ann Rheum Dis."},{"issue":"2","key":"6605_CR12","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1002\/acr.22401","volume":"67","author":"L Eder","year":"2015","unstructured":"Eder L, Thavaneswaran A, Chandran V, Cook R, Gladman DD (2015) Factors explaining the discrepancy between physician and patient global assessment of joint and skin disease activity in psoriatic arthritis patients. Arthritis Care Res (Hoboken). 67(2):264\u201372","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"1","key":"6605_CR13","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1136\/annrheumdis-2020-217344","volume":"80","author":"G Nagy","year":"2021","unstructured":"Nagy G, Roodenrijs NMT, Welsing PMJ, Kedves M, Hamar A, Van Der Goes MC et al (2021) EULAR definition of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis 80(1):31\u20135","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"6605_CR14","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1136\/annrheumdis-2019-216515","volume":"79","author":"S Safiri","year":"2020","unstructured":"Safiri S, Kolahi A-A, Smith E, Hill C, Bettampadi D, Mansournia MA et al (2020) Global, regional and national burden of osteoarthritis 1990\u20132017: a systematic analysis of the Global Burden of Disease Study 2017. Ann Rheum Dis 79(6):819\u201328","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"6605_CR15","doi-asserted-by":"publisher","first-page":"e000025","DOI":"10.1136\/rmdopen-2014-000025","volume":"1","author":"DJ Veale","year":"2015","unstructured":"Veale DJ, Fearon U (2015) What makes psoriatic and rheumatoid arthritis so different? RMD Open. 1(1):e000025","journal-title":"RMD Open."},{"issue":"8","key":"6605_CR16","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1136\/annrheumdis-2014-205212","volume":"74","author":"JF Merola","year":"2015","unstructured":"Merola JF, Wu S, Han J, Choi HK, Qureshi AA (2015) Psoriasis, psoriatic arthritis and risk of gout in US men and women. Ann Rheum Dis 74(8):1495\u2013500","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"6605_CR17","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s40744-018-0132-4","volume":"6","author":"LJ Tucker","year":"2019","unstructured":"Tucker LJ, Coates LC, Helliwell PS (2019) Assessing disease activity in psoriatic arthritis: a literature review. Rheumatol Ther 6(1):23\u201332","journal-title":"Rheumatol Ther"},{"issue":"5","key":"6605_CR18","first-page":"1167","volume":"34","author":"DD Gladman","year":"2007","unstructured":"Gladman DD, Mease PJ, Strand V, Healy P, Helliwell PS, Fitzgerald O et al (2007) Consensus on a core set of domains for psoriatic arthritis. J Rheumatol 34(5):1167\u201370","journal-title":"J Rheumatol"},{"issue":"2","key":"6605_CR19","doi-asserted-by":"publisher","first-page":"e000765","DOI":"10.1136\/rmdopen-2018-000765","volume":"4","author":"S Puk\u0161i\u0107","year":"2018","unstructured":"Puk\u0161i\u0107 S, Bolton-King P, Sexton J, Michelsen B, Kvien TK, Hammer HB (2018) DAPSA and ultrasound show different perspectives of psoriatic arthritis disease activity: results from a 12-month longitudinal observational study in patients starting treatment with biological disease-modifying antirheumatic drugs. RMD open. 4(2):e000765","journal-title":"RMD open."},{"key":"6605_CR20","doi-asserted-by":"crossref","unstructured":"Kaeley GS, Eder L, Aydin SZ, Gutierrez M, Bakewell C (2018) editors. Enthesitis: a hallmark of psoriatic arthritis: Elsevier","DOI":"10.1016\/j.semarthrit.2017.12.008"},{"issue":"12","key":"6605_CR21","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1136\/annrheumdis-2018-213609","volume":"77","author":"PV Balint","year":"2018","unstructured":"Balint PV, Terslev L, Aegerter P, Bruyn GAW, Chary-Valckenaere I, Gandjbakhch F et al (2018) Reliability of a consensus-based ultrasound definition and scoring for enthesitis in spondyloarthritis and psoriatic arthritis: an OMERACT US initiative. Ann Rheum Dis 77(12):1730\u20135","journal-title":"Ann Rheum Dis"},{"key":"6605_CR22","doi-asserted-by":"crossref","unstructured":"Gutierrez M, Filippucci E, De Angelis R, Salaffi F, Filosa G, Ruta S, et al (2011) editors. Subclinical entheseal involvement in patients with psoriasis: an ultrasound study: Elsevier","DOI":"10.1016\/j.semarthrit.2010.05.009"},{"issue":"1","key":"6605_CR23","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1136\/ard.2007.075101","volume":"67","author":"P Gisondi","year":"2008","unstructured":"Gisondi P, Tinazzi I, El-Dalati G, Gallo M, Biasi D, Barbara LM et al (2008) Lower limb enthesopathy in patients with psoriasis without clinical signs of arthropathy: a hospital-based case\u2013control study. Ann Rheum Dis 67(1):26\u201330","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"6605_CR24","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.3899\/jrheum.110505","volume":"38","author":"I Tinazzi","year":"2011","unstructured":"Tinazzi I, McGonagle D, Biasi D, Confente S, Caimmi C, Girolomoni G et al (2011) Preliminary evidence that subclinical enthesopathy may predict psoriatic arthritis in patients with psoriasis. J Rheumatol 38(12):2691\u20132","journal-title":"J Rheumatol"},{"issue":"6","key":"6605_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/ar2327","volume":"9","author":"C Wiell","year":"2007","unstructured":"Wiell C, Szkudlarek M, Hasselquist M, M\u00f8ller JM, Vestergaard A, N\u00f8rregaard J et al (2007) Ultrasonography, magnetic resonance imaging, radiography, and clinical assessment of inflammatory and destructive changes in fingers and toes of patients with psoriatic arthritis. Arthritis Res Ther 9(6):1\u201313","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"6605_CR26","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.3899\/jrheum.080205","volume":"36","author":"MA Stone","year":"2009","unstructured":"Stone MA, White LM, Gladman DD, Inman RD, Chaya S, Lax M et al (2009) Significance of clinical evaluation of the metacarpophalangeal joint in relation to synovial\/bone pathology in rheumatoid and psoriatic arthritis detected by magnetic resonance imaging. J Rheumatol 36(12):2751\u20137","journal-title":"J Rheumatol"},{"issue":"1","key":"6605_CR27","doi-asserted-by":"publisher","first-page":"e001170","DOI":"10.1136\/rmdopen-2020-001170","volume":"6","author":"E Lubrano","year":"2020","unstructured":"Lubrano E, Scriffignano S, Azuaga AB, Ramirez J, Ca\u00f1ete JD, Perrotta FM (2020) Assessment of the Patient Acceptable Symptom State (PASS) in psoriatic arthritis: association with disease activity and quality of life indices. RMD open. 6(1):e001170","journal-title":"RMD open."},{"issue":"11","key":"6605_CR28","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.3899\/jrheum.140882","volume":"41","author":"A Ogdie","year":"2014","unstructured":"Ogdie A, Schwartzman S, Eder L, Maharaj AB, Zisman D, Raychaudhuri SP et al (2014) Comprehensive treatment of psoriatic arthritis: managing comorbidities and extraarticular manifestations. J Rheumatol. 41(11):2315\u201322","journal-title":"J Rheumatol."},{"issue":"4","key":"6605_CR29","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.rdc.2015.07.008","volume":"41","author":"ME Husni","year":"2015","unstructured":"Husni ME (2015) Comorbidities in psoriatic arthritis. Rheum Dis Clin 41(4):677\u201398","journal-title":"Rheum Dis Clin"},{"issue":"4","key":"6605_CR30","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1002\/acr.22185","volume":"66","author":"M Labitigan","year":"2014","unstructured":"Labitigan M, Bahce-Altuntas A, Kremer JM, Reed G, Greenberg JD, Jordan N et al (2014) Higher rates and clustering of abnormal lipids, obesity, and diabetes mellitus in psoriatic arthritis compared with rheumatoid arthritis. Arth Car & Res. 66(4):600\u20137","journal-title":"Arth Car & Res."},{"issue":"10","key":"6605_CR31","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1002\/acr.23171","volume":"69","author":"H Radner","year":"2017","unstructured":"Radner H, Lesperance T, Accortt NA, Solomon DH (2017) Incidence and prevalence of cardiovascular risk factors among patients with rheumatoid arthritis, psoriasis, or psoriatic arthritis. Arth Car Res. 69(10):1510\u20138","journal-title":"Arth Car Res."},{"issue":"1","key":"6605_CR32","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/acr.21711","volume":"65","author":"MN di Minno","year":"2013","unstructured":"di Minno MN, Peluso R, Iervolino S, Lupoli R, Russolillo A, Scarpa R et al (2013) Obesity and the prediction of minimal disease activity: a prospective study in psoriatic arthritis. Arth Car Res. 65(1):141\u20137","journal-title":"Arth Car Res."},{"issue":"5","key":"6605_CR33","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1136\/annrheumdis-2013-204448","volume":"74","author":"L Eder","year":"2015","unstructured":"Eder L, Thavaneswaran A, Chandran V, Cook RJ, Gladman DD (2015) Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis. Ann Rheum Dis. 74(5):813\u20137","journal-title":"Ann Rheum Dis."},{"issue":"5","key":"6605_CR34","doi-asserted-by":"publisher","first-page":"e0195123","DOI":"10.1371\/journal.pone.0195123","volume":"13","author":"S Singh","year":"2018","unstructured":"Singh S, Facciorusso A, Singh AG, Vande Casteele N, Zarrinpar A, Prokop LJ et al (2018) Obesity and response to anti-tumor necrosis factor-alpha agents in patients with select immune-mediated inflammatory diseases: a systematic review and meta-analysis. PLoS One. 13(5):e0195123","journal-title":"PLoS One."},{"key":"6605_CR35","doi-asserted-by":"crossref","unstructured":"Walsh JA, Wan MT, Willinger C, Husni ME, Scher JU, Reddy SM, et al (2019) Measuring outcomes in psoriatic arthritis: comparing Routine Assessment of Patient Index Data (RAPID3) and Psoriatic Arthritis Impact of Disease (PSAID). J Rheumatol","DOI":"10.3899\/jrheum.190219"},{"issue":"4","key":"6605_CR36","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s00296-021-04971-8","volume":"42","author":"K Gok","year":"2022","unstructured":"Gok K, Nas K, Tekeoglu I, Sunar I, Keskin Y, Kilic E et al (2022) Impact of obesity on quality of life, psychological status, and disease activity in psoriatic arthritis: a multi-center study. Rheumatology international. 42(4):659\u201368","journal-title":"Rheumatology international."},{"issue":"6","key":"6605_CR37","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1136\/annrheumdis-2012-202812","volume":"73","author":"MN Di Minno","year":"2014","unstructured":"Di Minno MN, Peluso R, Iervolino S, Russolillo A, Lupoli R, Scarpa R et al (2014) Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor alpha blockers. Ann Rheum Dis. 73(6):1157\u201362","journal-title":"Ann Rheum Dis."},{"issue":"1","key":"6605_CR38","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s10067-019-04734-8","volume":"39","author":"SS Zhao","year":"2020","unstructured":"Zhao SS, Miller N, Harrison N, Duffield SJ, Dey M, Goodson NJ (2020) Systematic review of mental health comorbidities in psoriatic arthritis. Clin Rheumatol 39(1):217\u201325","journal-title":"Clin Rheumatol"},{"issue":"4","key":"6605_CR39","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/nrrheum.2011.2","volume":"7","author":"RR Edwards","year":"2011","unstructured":"Edwards RR, Cahalan C, Mensing G, Smith M, Haythornthwaite JA (2011) Pain, catastrophizing, and depression in the rheumatic diseases. Nat Rev Rheumatol 7(4):216\u201324","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"6605_CR40","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s00403-019-01906-z","volume":"311","author":"A Duvetorp","year":"2019","unstructured":"Duvetorp A, \u00d8stergaard M, Skov L, Seifert O, Tveit KS, Danielsen K et al (2019) Quality of life and contact with healthcare systems among patients with psoriasis and psoriatic arthritis: results from the NORdic PAtient survey of Psoriasis and Psoriatic arthritis (NORPAPP). Arch Dermatol Res 311(5):351\u201360","journal-title":"Arch Dermatol Res"},{"issue":"5","key":"6605_CR41","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1002\/acr.21602","volume":"64","author":"JA Husted","year":"2012","unstructured":"Husted JA, Tom BD, Farewell VT, Gladman DD (2012) Longitudinal study of the bidirectional association between pain and depressive symptoms in patients with psoriatic arthritis. Arth Car Res. 64(5):758\u201365","journal-title":"Arth Car Res."},{"issue":"2","key":"6605_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/ar2670","volume":"11","author":"AA Saad","year":"2009","unstructured":"Saad AA, Ashcroft DM, Watson KD, Hyrich KL, Noyce PR, Symmons DPM (2009) Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register. Arth Res Ther 11(2):1\u20139","journal-title":"Arth Res Ther"},{"issue":"11","key":"6605_CR43","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1136\/annrheumdis-2017-211284","volume":"76","author":"B Michelsen","year":"2017","unstructured":"Michelsen B, Kristianslund EK, Sexton J, Hammer HB, Fagerli KM, Lie E et al (2017) Do depression and anxiety reduce the likelihood of remission in rheumatoid arthritis and psoriatic arthritis? Data from the prospective multicentre NOR-DMARD study. Ann Rheum Dis 76(11):1906\u201310","journal-title":"Ann Rheum Dis"},{"key":"6605_CR44","doi-asserted-by":"crossref","unstructured":"Wong A, Ye JY, Cook RJ, Gladman DD, Chandran V (2021) Depression and anxiety reduce the probability of achieving a state of sustained minimal disease activity in patients with psoriatic arthritis. Arth Car & Res","DOI":"10.1002\/acr.24593"},{"issue":"1","key":"6605_CR45","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s41927-019-0106-3","volume":"4","author":"P Brenner","year":"2020","unstructured":"Brenner P, Citarella A, Wing\u00e5rd L, Sundstr\u00f6m A (2020) Use of antidepressants and benzodiazepine-related hypnotics before and after initiation of TNF-\u03b1 inhibitors or non-biological systemic treatment in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. BMC rheumatology. 4(1):9","journal-title":"BMC rheumatology."},{"issue":"8","key":"6605_CR46","first-page":"1453","volume":"57","author":"SJ Duffield","year":"2018","unstructured":"Duffield SJ, Miller N, Zhao S, Goodson NJ (2018) Concomitant fibromyalgia complicating chronic inflammatory arthritis: a systematic review and meta-analysis. Rheumatology. 57(8):1453\u201360","journal-title":"Rheumatology."},{"issue":"2","key":"6605_CR47","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/ced.12504","volume":"40","author":"D Graceffa","year":"2015","unstructured":"Graceffa D, Maiani E, Sperduti I, Ceralli F, Bonifati C (2015) Clinical remission of psoriatic arthritis in patients receiving continuous biological therapies for 1 year: the experience of an outpatient dermatological clinic for psoriasis. Clin Exp Dermatol 40(2):136\u201341","journal-title":"Clin Exp Dermatol"},{"issue":"9","key":"6605_CR48","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.3899\/jrheum.151491","volume":"43","author":"S Brikman","year":"2016","unstructured":"Brikman S, Furer V, Wollman J, Borok S, Matz H, Polachek A et al (2016) The effect of the presence of fibromyalgia on common clinical disease activity indices in patients with psoriatic arthritis: a cross-sectional study. J Rheumatol 43(9):1749\u201354","journal-title":"J Rheumatol"},{"issue":"2","key":"6605_CR49","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/1756-185X.13987","volume":"24","author":"NA Elsawy","year":"2021","unstructured":"Elsawy NA, Helal AMH, Abd ElHamid HA, Abdel-Fattah YH (2021) Fibromyalgia in patients with psoriatic arthritis: impact on disease activity indices, fatigue and health-related quality of life. Int J Rheum Dis 24(2):189\u201396","journal-title":"Int J Rheum Dis"},{"issue":"1","key":"6605_CR50","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3109\/09546634.2011.607425","volume":"24","author":"SA Chan","year":"2013","unstructured":"Chan SA, Hussain F, Lawson LG, Ormerod AD (2013) Factors affecting adherence to treatment of psoriasis: comparing biologic therapy to other modalities. J Dermatol Treatment 24(1):64\u20139","journal-title":"J Dermatol Treatment"},{"issue":"12","key":"6605_CR51","doi-asserted-by":"publisher","first-page":"e80633","DOI":"10.1371\/journal.pone.0080633","volume":"8","author":"R Horne","year":"2013","unstructured":"Horne R, Chapman SCE, Parham R, Freemantle N, Forbes A, Cooper V (2013) Understanding patients\u2019 adherence-related beliefs about medicines prescribed for long-term conditions: a meta-analytic review of the Necessity-Concerns Framework. PloS one. 8(12):e80633","journal-title":"PloS one."},{"issue":"8","key":"6605_CR52","doi-asserted-by":"publisher","first-page":"607","DOI":"10.2217\/cer-2019-0023","volume":"8","author":"KR Oelke","year":"2019","unstructured":"Oelke KR, Chambenoit O, Majjhoo AQ, Gray S, Higgins K, Hur P (2019) Persistence and adherence of biologics in US patients with psoriatic arthritis: analyses from a claims database. J Comparative Effect Res 8(8):607\u201321","journal-title":"J Comparative Effect Res"},{"issue":"11","key":"6605_CR53","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1007\/s12325-015-0256-7","volume":"32","author":"E Vangeli","year":"2015","unstructured":"Vangeli E, Bakhshi S, Baker A, Fisher A, Bucknor D, Mrowietz U et al (2015) A systematic review of factors associated with non-adherence to treatment for immune-mediated inflammatory diseases. Adv Ther 32(11):983\u20131028","journal-title":"Adv Ther"},{"issue":"3","key":"6605_CR54","doi-asserted-by":"publisher","first-page":"166","DOI":"10.4103\/ds.ds_27_20","volume":"38","author":"CY Ng","year":"2020","unstructured":"Ng CY, Huang Y-H, Tzeng IS, Liu S-H, Chang Y-C (2020) Changes in metabolic parameters in psoriasis patients treated with interleukin-12\/23 blockade (ustekinumab). Dermatologica Sinica. 38(3):166","journal-title":"Dermatologica Sinica."},{"issue":"10","key":"6605_CR55","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1007\/s11606-012-2077-6","volume":"27","author":"G Elwyn","year":"2012","unstructured":"Elwyn G, Frosch D, Thomson R, Joseph-Williams N, Lloyd A, Kinnersley P et al (2012) Shared decision making: a model for clinical practice. J General Int Med 27(10):1361\u20137","journal-title":"J General Int Med"},{"key":"6605_CR56","doi-asserted-by":"crossref","unstructured":"Coates LC, O'Dwyer J, Meads D, Emery P, Conaghan PG, Helliwell PS (2022) Treat-to-target in psoriatic arthritis\u2014cost-effective in the biosimilar era. The Lancet Rheumatology","DOI":"10.1016\/S2665-9913(22)00101-1"},{"issue":"6","key":"6605_CR57","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.reuma.2021.03.006","volume":"17","author":"W Bautista-Molano","year":"2021","unstructured":"Bautista-Molano W (2021) Treatment of psoriatic arthritis: challenges in Latin America. Reumatologia Clinica. 17(6):307\u20138","journal-title":"Reumatologia Clinica."},{"issue":"9","key":"6605_CR58","doi-asserted-by":"publisher","first-page":"3411","DOI":"10.1007\/s10067-021-05841-1","volume":"40","author":"AB Maharaj","year":"2021","unstructured":"Maharaj AB, Adebajo A (2021) Psoriatic arthritis in Africa. Clin Rheumatol 40(9):3411\u20138","journal-title":"Clin Rheumatol"},{"key":"6605_CR59","doi-asserted-by":"crossref","unstructured":"Sumpton D, Oliffe M, Kane B, Hassett G, Craig JC, Kelly A, et al (2021) Patients\u2019 perspectives on shared decision-making about medications in psoriatic arthritis: an interview study. Arth Car & Res","DOI":"10.1002\/acr.24748"},{"issue":"1","key":"6605_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-016-1138-3","volume":"18","author":"I Nota","year":"2016","unstructured":"Nota I, Drossaert CHC, Taal E, Vonkeman HE, Haagsma CJ, van de Laar MAFJ (2016) Evaluation of a patient decision aid for initiating disease modifying anti-rheumatic drugs. Arth Res Ther 18(1):1\u201312","journal-title":"Arth Res Ther"},{"key":"6605_CR61","doi-asserted-by":"crossref","unstructured":"Stacey D, L\u00e9gar\u00e9 F, Lewis K, Barry MJ, Bennett CL, Eden KB, et al (2017) Decision aids for people facing health treatment or screening decisions. Cochrane database of systematic reviews. (4)","DOI":"10.1002\/14651858.CD001431.pub5"},{"issue":"8","key":"6605_CR62","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1093\/rheumatology\/kes001","volume":"51","author":"GH Kingsley","year":"2012","unstructured":"Kingsley GH, Kowalczyk A, Taylor H, Ibrahim F, Packham JC, McHugh NJ et al (2012) A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology. 51(8):1368\u201377","journal-title":"Rheumatology."},{"issue":"10012","key":"6605_CR63","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1016\/S0140-6736(15)00347-5","volume":"386","author":"LC Coates","year":"2015","unstructured":"Coates LC, Moverley AR, McParland L, Brown S, Navarro-Coy N, O\u2019Dwyer JL et al (2015) Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. Lancet. 386(10012):2489\u201398","journal-title":"Lancet."},{"issue":"4","key":"6605_CR64","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1136\/ard.2011.152223","volume":"71","author":"A Baranauskaite","year":"2012","unstructured":"Baranauskaite A, Raffayov\u00e1 H, Kungurov NV, Kubanova A, Venalis A, Helmle L et al (2012) Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study. Ann Rheum Dis 71(4):541\u20138","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"6605_CR65","first-page":"481","volume":"33","author":"M Hoekstra","year":"2006","unstructured":"Hoekstra M, Haagsma C, Neef C, Proost J, Knuif A, van de Laar M (2006) Splitting high-dose oral methotrexate improves bioavailability: a pharmacokinetic study in patients with rheumatoid arthritis. J Rheumatol 33(3):481\u20135","journal-title":"J Rheumatol"},{"issue":"9","key":"6605_CR66","doi-asserted-by":"publisher","first-page":"e0221823","DOI":"10.1371\/journal.pone.0221823","volume":"14","author":"AM Bujor","year":"2019","unstructured":"Bujor AM, Janjua S, LaValley MP, Duran J, Braun J, Felson DT (2019) Comparison of oral versus parenteral methotrexate in the treatment of rheumatoid arthritis: a meta-analysis. PloS one. 14(9):e0221823","journal-title":"PloS one."},{"issue":"2","key":"6605_CR67","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/art.22379","volume":"56","author":"DD Gladman","year":"2007","unstructured":"Gladman DD, Mease PJ, Ritchlin CT, Choy EHS, Sharp JT, Ory PA et al (2007) Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arth Rheum: Off J Am College Rheumatol 56(2):476\u201388","journal-title":"Arth Rheum: Off J Am College Rheumatol"},{"issue":"9999","key":"6605_CR68","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","volume":"386","author":"IB McInnes","year":"2015","unstructured":"McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P et al (2015) Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. 386(9999):1137\u201346","journal-title":"The Lancet."},{"issue":"9","key":"6605_CR69","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1136\/annrheumdis-2016-210724","volume":"76","author":"PJ Mease","year":"2017","unstructured":"Mease PJ, Gottlieb AB, van der Heijde D, FitzGerald O, Johnsen A, Nys M et al (2017) Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis. Ann Rheum Dis 76(9):1550\u20138","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"6605_CR70","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.berh.2019.03.001","volume":"32","author":"O FitzGerald","year":"2018","unstructured":"FitzGerald O, Ritchlin C (2018) Opportunities and challenges in the treatment of psoriatic arthritis. Best Pract Res Clin Rheumatol 32(3):440\u201352","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"9894","key":"6605_CR71","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","volume":"382","author":"IB McInnes","year":"2013","unstructured":"McInnes IB, Kavanaugh A, Gottlieb AB, Puig L, Rahman P, Ritchlin C et al (2013) Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet. 382(9894):780\u20139","journal-title":"Lancet."},{"issue":"10","key":"6605_CR72","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1586\/1744666X.2013.836060","volume":"9","author":"L Hsu","year":"2013","unstructured":"Hsu L, Armstrong AW (2013) Anti-drug antibodies in psoriasis: a critical evaluation of clinical significance and impact on treatment response. Exp Rev Clin Immunol 9(10):949\u201358","journal-title":"Exp Rev Clin Immunol"},{"issue":"10","key":"6605_CR73","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1007\/s10067-013-2336-x","volume":"32","author":"CC Mok","year":"2013","unstructured":"Mok CC, Van Der Kleij D, Wolbink GJ (2013) Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNF\u03b1 biologics in rheumatic diseases. Clin Rheumatol 32(10):1429\u201335","journal-title":"Clin Rheumatol"},{"issue":"16","key":"6605_CR74","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","volume":"377","author":"P Mease","year":"2017","unstructured":"Mease P, Hall S, FitzGerald O, van der Heijde D, Merola JF, Avila-Zapata F et al (2017) Tofacitinib or adalimumab versus placebo for psoriatic arthritis. New Eng J Med 377(16):1537\u201350","journal-title":"New Eng J Med"},{"issue":"3","key":"6605_CR75","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1136\/annrheumdis-2020-218870","volume":"80","author":"PJ Mease","year":"2021","unstructured":"Mease PJ, Lertratanakul A, Anderson JK, Papp K, Van den Bosch F, Tsuji S et al (2021) Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2. Ann Rheum Dis 80(3):312\u201320","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"6605_CR76","doi-asserted-by":"publisher","first-page":"5023","DOI":"10.1021\/jm401490p","volume":"57","author":"JD Clark","year":"2014","unstructured":"Clark JD, Flanagan ME, Telliez J-B (2014) Discovery and development of Janus Kinase (JAK) inhibitors for inflammatory diseases: Miniperspective. J Med Chem 57(12):5023\u201338","journal-title":"J Med Chem"},{"key":"6605_CR77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-019-1964-1","volume":"21","author":"IB McInnes","year":"2019","unstructured":"McInnes IB, Byers NL, Higgs RE, Lee J, Macias WL, Na S et al (2019) Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations. Arth Res Ther 21:1\u201310","journal-title":"Arth Res Ther"},{"key":"6605_CR78","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1007\/s10067-019-04870-1","volume":"39","author":"ER Soriano","year":"2020","unstructured":"Soriano ER, Zazzetti F, Alves Pereira I, Maldonado Cocco J, Feij\u00f3 Azevedo V, Guerra G et al (2020) Physician-patient alignment in satisfaction with psoriatic arthritis treatment in Latin America. Clin Rheumatol 39:1859\u201369","journal-title":"Clin Rheumatol"},{"issue":"12","key":"6605_CR79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11926-019-0876-z","volume":"21","author":"C Ritchlin","year":"2019","unstructured":"Ritchlin C, Scher JU (2019) Strategies to improve outcomes in psoriatic arthritis. Curr Rheumatol Rep 21(12):1\u20138","journal-title":"Curr Rheumatol Rep"},{"issue":"11","key":"6605_CR80","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1002\/art.40579","volume":"70","author":"PJ Mease","year":"2018","unstructured":"Mease PJ, Genovese MC, Weinblatt ME, Peloso PM, Chen K, Othman AA et al (2018) Phase II study of ABT-122, a tumor necrosis factor\u2013and interleukin-17A\u2013targeted dual variable domain immunoglobulin, in patients with psoriatic arthritis with an inadequate response to methotrexate. Arth Rheumatol 70(11):1778\u201389","journal-title":"Arth Rheumatol"},{"issue":"11","key":"6605_CR81","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1093\/rheumatology\/key173","volume":"57","author":"MC Genovese","year":"2018","unstructured":"Genovese MC, Weinblatt ME, Mease PJ, Aelion JA, Peloso PM, Chen K et al (2018) Dual inhibition of tumour necrosis factor and interleukin-17A with ABT-122: open-label long-term extension studies in rheumatoid arthritis or psoriatic arthritis. Rheumatology. 57(11):1972\u201381","journal-title":"Rheumatology."},{"issue":"2","key":"6605_CR82","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1056\/NEJMoa0810652","volume":"362","author":"CEM Griffiths","year":"2010","unstructured":"Griffiths CEM, Strober BE, Van De Kerkhof P, Ho V, Fidelus-Gort R, Yeilding N et al (2010) Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. New Eng J Med 362(2):118\u201328","journal-title":"New Eng J Med"},{"issue":"2","key":"6605_CR83","doi-asserted-by":"publisher","first-page":"e000723","DOI":"10.1136\/rmdopen-2018-000723","volume":"4","author":"PJ Mease","year":"2018","unstructured":"Mease PJ, Kavanaugh A, Reimold A, Tahir H, Rech J, Hall S et al (2018) Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial. RMD open. 4(2):e000723","journal-title":"RMD open."},{"issue":"10","key":"6605_CR84","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.jdcr.2019.08.015","volume":"5","author":"Q Thibodeaux","year":"2019","unstructured":"Thibodeaux Q, Ly K, Reddy V, Smith MP, Liao W (2019) Dual biologic therapy for recalcitrant psoriasis and psoriatic arthritis. JAAD Case Rep 5(10):928\u201330","journal-title":"JAAD Case Rep"},{"issue":"10","key":"6605_CR85","doi-asserted-by":"publisher","first-page":"e15759","DOI":"10.1111\/dth.15759","volume":"35","author":"F Diotallevi","year":"2022","unstructured":"Diotallevi F, Paolinelli M, Radi G, Offidani A (2022) Latest combination therapies in psoriasis: Narrative review of the literature. Dermatol Ther 35(10):e15759","journal-title":"Dermatol Ther"},{"issue":"9","key":"6605_CR86","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1002\/art.41765","volume":"73","author":"JU Scher","year":"2021","unstructured":"Scher JU, Ogdie A, Merola JF, Ritchlin C (2021) Moving the goalpost toward remission: the case for combination immunomodulatory therapies in psoriatic arthritis. Arth Rheumatol 73(9):1574\u20138","journal-title":"Arth Rheumatol"},{"issue":"Supplement_1","key":"6605_CR87","doi-asserted-by":"publisher","first-page":"i042","DOI":"10.1093\/ecco-jcc\/jjab232.035","volume":"16","author":"BE Sands","year":"2022","unstructured":"Sands BE, Feagan BG, Sandborn WJ, Shipitofsky N, Marko M, Sheng S et al (2022) OP36 Efficacy and safety of combination induction therapy with guselkumab and golimumab in participants with moderately-to-severely active ulcerative colitis: results through week 12 of a phase 2a randomized, double-blind, active-controlled, parallel-group, multicenter, proof-of-concept study. J Crohn\u2019s Colitis 16(Supplement_1):i042-i3","journal-title":"J Crohn\u2019s Colitis"},{"issue":"10341","key":"6605_CR88","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","volume":"399","author":"S Danese","year":"2022","unstructured":"Danese S, Vermeire S, Zhou W, Pangan AL, Siffledeen J, Greenbloom S et al (2022) Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet 399(10341):2113\u201328","journal-title":"Lancet"},{"issue":"2","key":"6605_CR89","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1177\/0394632015593220","volume":"29","author":"F Carubbi","year":"2016","unstructured":"Carubbi F, Zugaro L, Cipriani P, Conchiglia A, Gregori L, Danniballe C et al (2016) Safety and efficacy of intra-articular anti-tumor necrosis factor \u03b1 agents compared to corticosteroids in a treat-to-target strategy in patients with inflammatory arthritis and monoarthritis flare. Int J Immunopathol Pharmacol 29(2):252\u201366","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"12","key":"6605_CR90","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1111\/1346-8138.13975","volume":"44","author":"T Kanekura","year":"2017","unstructured":"Kanekura T, Seishima M, Honma M, Etou T, Eto H, Okuma K et al (2017) Therapeutic depletion of myeloid lineage leukocytes by adsorptive apheresis for psoriatic arthritis: efficacy of a non-drug intervention for patients refractory to pharmacologics. J Dermatol 44(12):1353\u20139","journal-title":"J Dermatol"},{"key":"6605_CR91","doi-asserted-by":"crossref","unstructured":"McInnes I, Coates L, Landew\u00e9 RBM, Mease PJ, Ritchlin CT, Tanaka Y, et al (2022) LB0001 bimekizumab in BDMARD-naive patients with psoriatic arthritis: 24-week efficacy & safety from be optimal, a phase 3, multicentre, randomised, placebo-controlled, active reference study. BMJ Publishing Group Ltd","DOI":"10.1136\/annrheumdis-2022-eular.5016"},{"issue":"10370","key":"6605_CR92","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S0140-6736(22)02303-0","volume":"401","author":"JF Merola","year":"2023","unstructured":"Merola JF, Landew\u00e9 R, McInnes IB, Mease PJ, Ritchlin CT, Tanaka Y et al (2023) Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-\u03b1 inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE). Lancet 401(10370):38\u201348","journal-title":"Lancet"},{"issue":"6","key":"6605_CR93","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1136\/annrheumdis-2021-221664","volume":"81","author":"PJ Mease","year":"2022","unstructured":"Mease PJ, Deodhar AA, van der Heijde D, Behrens F, Kivitz AJ, Neal J et al (2022) Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis. Ann Rheum Dis 81(6):815\u201322","journal-title":"Ann Rheum Dis"},{"key":"6605_CR94","doi-asserted-by":"crossref","unstructured":"Behrens F, Taylor PC, Wetzel D, Brun NC, Brandt-Juergens J, Drescher E, et al (2022) OP0258 Izokibep (ABY-035) in patients with active psoriatic arthritis\u201316-week results from a phase 2 study. BMJ Publishing Group Ltd","DOI":"10.1136\/annrheumdis-2022-eular.536"},{"key":"6605_CR95","doi-asserted-by":"crossref","unstructured":"Hutton J, Mease P, Jadon D (2022) Horizon scan: state-of-the-art therapeutics for psoriatic arthritis. Best Pract Res Clin Rheumatol. 101809","DOI":"10.1016\/j.berh.2022.101809"},{"issue":"10284","key":"6605_CR96","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/S0140-6736(21)00440-2","volume":"397","author":"KA Papp","year":"2021","unstructured":"Papp KA, Weinberg MA, Morris A, Reich K (2021) IL17A\/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study. Lancet. 397(10284):1564\u201375","journal-title":"Lancet."},{"issue":"11","key":"6605_CR97","doi-asserted-by":"publisher","first-page":"e677","DOI":"10.1016\/S2665-9913(20)30229-0","volume":"2","author":"CD Buckley","year":"2020","unstructured":"Buckley CD, Sim\u00f3n-Campos JA, Zhdan V, Becker B, Davy K, Fisheleva E et al (2020) Efficacy, patient-reported outcomes, and safety of the anti-granulocyte macrophage colony-stimulating factor antibody otilimab (GSK3196165) in patients with rheumatoid arthritis: a randomised, phase 2b, dose-ranging study. Lancet Rheumatol 2(11):e677\u2013e88","journal-title":"Lancet Rheumatol"},{"key":"6605_CR98","doi-asserted-by":"publisher","first-page":"613975","DOI":"10.3389\/fimmu.2020.613975","volume":"11","author":"S Fuentelsaz-Romero","year":"2021","unstructured":"Fuentelsaz-Romero S, Cuervo A, Estrada-Capetillo L, Celis R, Garc\u00eda-Campos R, Ram\u00edrez J et al (2021) GM-CSF expression and macrophage polarization in joints of undifferentiated arthritis patients evolving to rheumatoid arthritis or psoriatic arthritis. Front Immunol 11:613975","journal-title":"Front Immunol"},{"key":"6605_CR99","doi-asserted-by":"crossref","unstructured":"Buttgereit F, Aelion J, Rojkovich B, Zubrzycka-Sienkiewicz A, Radstake T, Chen S, et al (2021) OP0115 efficacy and safety of ABBV-3373, a novel anti-tnf glucocorticoid receptor modulator antibody drug conjugate, in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy: a phase 2a proof of concept study. BMJ Publishing Group Ltd","DOI":"10.1136\/annrheumdis-2021-eular.221"},{"issue":"1","key":"6605_CR100","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1186\/1471-2458-13-449","volume":"13","author":"F Sun","year":"2013","unstructured":"Sun F, Norman IJ, While AE (2013) Physical activity in older people: a systematic review. BMC Public Health 13(1):449","journal-title":"BMC Public Health"},{"issue":"9","key":"6605_CR101","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1093\/gerona\/glx121","volume":"73","author":"B Olaya","year":"2018","unstructured":"Olaya B, Moneta MV, Dom\u00e9nech-Abella J, Miret M, Bayes I, Ayuso-Mateos JL et al (2018) Mobility difficulties, physical activity, and all-cause mortality risk in a nationally representative sample of older adults. J Gerontol A Biol Sci Med Sci 73(9):1272\u20139","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"6605_CR102","doi-asserted-by":"publisher","first-page":"m2031","DOI":"10.1136\/bmj.m2031","volume":"370","author":"M Zhao","year":"2020","unstructured":"Zhao M, Veeranki SP, Magnussen CG, Xi B (2020) Recommended physical activity and all cause and cause specific mortality in US adults: prospective cohort study. Bmj. 370:m2031","journal-title":"Bmj."},{"issue":"19","key":"6605_CR103","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1001\/jama.2018.14854","volume":"320","author":"KL Piercy","year":"2018","unstructured":"Piercy KL, Troiano RP, Ballard RM, Carlson SA, Fulton JE, Galuska DA et al (2018) The physical activity guidelines for Americans. Jama. 320(19):2020\u20138","journal-title":"Jama."},{"issue":"9","key":"6605_CR104","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1136\/annrheumdis-2018-213585","volume":"77","author":"AK Rausch Osthoff","year":"2018","unstructured":"Rausch Osthoff AK, Niedermann K, Braun J, Adams J, Brodin N, Dagfinrud H et al (2018) 2018 EULAR recommendations for physical activity in people with inflammatory arthritis and osteoarthritis. Ann Rheum Dis 77(9):1251\u201360","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"6605_CR105","doi-asserted-by":"publisher","first-page":"237","DOI":"10.3109\/03009749409103722","volume":"23","author":"A H\u00e4kkinen","year":"1994","unstructured":"H\u00e4kkinen A, H\u00e4kkinen K, Hannonen P (1994) Effects of strength training on neuromuscular function and disease activity in patients with recent-onset inflammatory arthritis. Scandinavian J Rheumatol 23(5):237\u201342","journal-title":"Scandinavian J Rheumatol"},{"issue":"4","key":"6605_CR106","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1002\/acr.23614","volume":"71","author":"RS Thomsen","year":"2019","unstructured":"Thomsen RS, Nilsen TIL, Haugeberg G, Bye A, Kavanaugh A, Hoff M (2019) Impact of high-intensity interval training on disease activity and disease in patients with psoriatic arthritis: a randomized controlled trial. Arth Car Res 71(4):530\u20137","journal-title":"Arth Car Res"},{"issue":"11","key":"6605_CR107","doi-asserted-by":"publisher","first-page":"4379","DOI":"10.1007\/s10067-021-05739-y","volume":"40","author":"J Kessler","year":"2021","unstructured":"Kessler J, Chouk M, Ruban T, Prati C, Wendling D, Verhoeven F (2021) Psoriatic arthritis and physical activity: a systematic review. Clin Rheumatol 40(11):4379\u201389","journal-title":"Clin Rheumatol"},{"key":"6605_CR108","doi-asserted-by":"crossref","unstructured":"Kumthekar A, Pedro S, Michaud K, Ozen G, Katz P, Baker J, et al (2023) Physical activity habits among older adults living with rheumatic disease. J Rheumatol","DOI":"10.3899\/jrheum.211244"},{"issue":"6","key":"6605_CR109","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s00296-019-04458-7","volume":"40","author":"F Caso","year":"2020","unstructured":"Caso F, Navarini L, Carubbi F, Picchianti-Diamanti A, Chimenti MS, Tasso M et al (2020) Mediterranean diet and psoriatic arthritis activity: a multicenter cross-sectional study. Rheumatol Int 40(6):951\u20138","journal-title":"Rheumatol Int"},{"issue":"8","key":"6605_CR110","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1001\/jamadermatol.2018.1412","volume":"154","author":"AR Ford","year":"2018","unstructured":"Ford AR, Siegel M, Bagel J, Cordoro KM, Garg A, Gottlieb A et al (2018) Dietary recommendations for adults with psoriasis or psoriatic arthritis from the medical board of the national psoriasis foundation: a systematic review. JAMA dermatol 154(8):934\u201350","journal-title":"JAMA dermatol"}],"updated-by":[{"DOI":"10.1007\/s10067-023-06627-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T00:00:00Z","timestamp":1683763200000}}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-023-06605-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-023-06605-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-023-06605-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T08:07:07Z","timestamp":1691568427000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-023-06605-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,25]]},"references-count":110,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["6605"],"URL":"https:\/\/doi.org\/10.1007\/s10067-023-06605-9","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,25]]},"assertion":[{"value":"17 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2023","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s10067-023-06627-3","URL":"https:\/\/doi.org\/10.1007\/s10067-023-06627-3","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Anand Kumthekar and Maedeh Ashrafi declare no conflict of interest. Atul Deodhar: Consulting, Advisory Boards: AbbVie, Amgen, Aurinia, Bristol Myers Squibb, Eli Lilly, Janssen, MoonLake, Novartis, Pfizer, UCB. Research Grants: AbbVie, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, MoonLake, Novartis, Pfizer, UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}